Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Genetic switch increases blood vessels in skeletal muscle of non-exercising mice

Genetic switch increases blood vessels in skeletal muscle of non-exercising mice

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Study: Gastric bypass surgery may lead to better health outcomes in patients with diabetes

Study: Gastric bypass surgery may lead to better health outcomes in patients with diabetes

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Leading foundations support Australian diabetes treatment

Leading foundations support Australian diabetes treatment

Lakewood Regional Medical Center supports 'Focus on the Heart' campaign

Lakewood Regional Medical Center supports 'Focus on the Heart' campaign

Scientists develop novel approach to detect long-distance chromosomal interactions for CAD

Scientists develop novel approach to detect long-distance chromosomal interactions for CAD

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Kaiser Permanente receives $3 million CDC grant to continue SEARCH study for childhood diabetes

Kaiser Permanente receives $3 million CDC grant to continue SEARCH study for childhood diabetes

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

First Round Table Meeting on Metabolomics & Diabetes takes place in Vienna

First Round Table Meeting on Metabolomics & Diabetes takes place in Vienna

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.